Advanced search
Publication Cover
Journal of Medical Economics Volume 17, 2014 - Issue 6
Submit an article Journal homepage
1,101
Views
7
CrossRef citations to date
0
Altmetric
Oncology: Original article

Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain

Emmanuel GimenezAntares-Consulting BarcelonaSpainCorrespondence[email protected]
,
Carles BessesHospital del Mar BarcelonaSpain
,
Concepcion BoqueInstitut Català d’Oncologia, Hospitalet LlobregatSpain
,
Patricia VelezInstitut Català d’Oncologia, Hospitalet LlobregatSpain
,
Ana KerguelenHospital La Paz MadridSpain
,
Francisco CervantesHospital Clinic, BarcelonaSpain
,
Francisca Ferrer-MarinHospital Universitario Morales Meseguer MurciaSpain
,
Manuel Perez-EncinasComplexo Hospitalario Universitario de Santiago SantiagoSpain
,
Mercedes RodriguezHospital de Navarra PamplonaSpain
,
Juan Diego GonzalezAntares-Consulting BarcelonaSpain
,
Reyes CalzadaNovartis Farmaceutica BarcelonaSpain
&
Juan Carlos Hernandez-BoludaHospital Clinico Universitario de Valencia ValenciaSpain
 show all
Pages 435-441 | Accepted 06 Mar 2014, Published online: 09 Apr 2014

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Junnan Jiang, Shanquan Chen, Yanjiao Xin, Xuefeng Wang, Li Zeng, Zhengdong Zhong & Li Xiang. (2019) Does the critical illness insurance reduce patients’ financial burden and benefit the poor more: a comprehensive evaluation in rural area of China. Journal of Medical Economics 22:5, pages 455-463.
Read now
Björn Vandewalle, Valeska Andreozzi, João Almeida & Jorge Félix. (2016) Pharmacoeconomics of ruxolitinib therapy in patients with myelofibrosis. Journal of Medical Economics 19:4, pages 424-431.
Read now

Articles from other publishers (5)

Sarah Friis Christensen, Lise Skovgaard Svingel, Anders Kjærsgaard, Anna Stenling, Bianka Darvalics, Björn Paulsson, Christen Lykkegaard Andersen, Christian Fynbo Christiansen, Jesper Stentoft, Jørn Starklint, Marianne Tang Severinsen, Mette Borg Clausen, Morten Hagemann Hilsøe, Hans Carl Hasselbalch, Henrik Frederiksen, Ellen Margrethe Mikkelsen & Marie Bak. (2022) Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study. European Journal of Haematology 109:5, pages 526-541.
Crossref
Ana Rita Sequeira, Emmanouil Mentzakis, Olga Archangelidi & Francesco Paolucci. (2021) The economic and health impact of rare diseases: A meta-analysis. Health Policy and Technology 10:1, pages 32-44.
Crossref
Ruben A. Mesa, Yun Su, Adrien Woolfson, Josef T. Prchal, Kathleen Turnbull, Elias Jabbour, Robyn Scherber, Alan L. Shields, Meaghan Krohe, Funke Ojo, Farrah Pompilus, Joseph C. Cappelleri & Claire Harrison. (2019) Development of a symptom assessment in patients with myelofibrosis: qualitative study findings. Health and Quality of Life Outcomes 17:1.
Crossref
Francesca Palandri, Giulia Benevolo, Alessandra Iurlo, Elisabetta Abruzzese, Angelo M. Carella, Chiara Paoli, Giuseppe A. Palumbo, Massimiliano Bonifacio, Daniela Cilloni, Alessandro Andriani, Attilio Guarini, Diamante Turri, Elena Maria Elli, Antonietta Falcone, Barbara Anaclerico, Pellegrino Musto, Nicola Di Renzo, Mario Tiribelli, Renato Zambello, Caterina Spinosa, Alessandra Ricco, Letizia Raucci, Bruno Martino, Mario Annunziata, Silvia Pascale, Anna Marina Liberati, Giorgio La Nasa, Margherita Maffioli, Massimo Breccia, Novella Pugliese, Silvia Betti, Gianfranco Giglio, Antonietta Cappuccio & Luigi Reale. (2018) Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project. Quality of Life Research 27:6, pages 1545-1554.
Crossref
María Teresa Gómez-Casares, Juan Carlos Hernández-Boluda, Antonio Jiménez-Velasco, Joaquin Martínez-López, María Giovanna Ferrario, Irmina Gozalbo, Joana Gostkorzewicz & Rudi Subirá. (2017) Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. Journal of Health Economics and Outcomes Research 5:2, pages 162-174.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.